In phase II trials, PXL01 (derived from human lactoferricin) has been used for the prevention of post-surgical adhesion formation in hand surgery (CTI: NCT01022242); and PAC-113 (derived from the human saliva histatin 3) has been used to treat oral candidiasis in HIV seropositive patients (CTI: NCT00659971). The gene discussed is HTN3; the disease is oral candidiasis.